C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
2.
CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTOR
Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codon-optimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.
C12N 15/67 - Méthodes générales pour favoriser l'expression
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
The present disclosure provides engineered human cells (e.g., T cells) for treatment. Also provided are expression constructs for making the engineered cells.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
T CELLS COMPRISING A CHIMERIC ANTIGEN RECEPTOR TARGETING TRANSFORMING GROWTH FACTOR BETA AND A T CELL RECEPTOR TARGETING A TUMOR ANTIGEN, AND USE THEREOF
The present disclosure relates to a T cell comprising (i) a chimeric antigen receptors (CAR) targeting transforming growth factor-β (TGF-β) and (ii) a T cell receptor (TCR) targeting a tumor antigen, e.g., a human papillomavirus (HPV) E7 antigen. The presence of the TGF-β CAR enhances the TCRmediated cytotoxicity and suppresses the differentiation of regulatory T cells (Tregs). Also disclosed are methods of administering the T cells to treat a cancer.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
6.
BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF
The present disclosure relates to bispecific chimeric antigen receptors (CARs) targeting both Claudin-18 splice variant 18.2 (CLDN18.2) and transforming growth factor-β (TGF-β). Also disclosed are chimeric antigen receptor (CAR) T cells expressing the bispecific CAR and methods of treating gastric cancer by administering the CAR T cells to a subject in need thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The preset disclosure provides methods of culturing TILs by first culturing a tumor sample in a first expansion medium, wherein the first expansion medium comprises a CD3 agonist and APCs at a first ratio (a "first REP step"); and culturing the TILs from first REP step in a second expansion medium, wherein the second expansion medium comprises a CD3 agonist and APCs at a second ratio (a "second REP step"). In some aspects, the methods disclosed herein enhance expansion of CD8+ TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof.
The present disclosure provides IL-12 stability variants, nucleic acids encoding the variants, vectors comprising the nucleic acids, pharmaceutical compositions comprising the variants, therapeutic cells expressing the variants, and methods or uses of the same for the treatment or prevention of a disease or disorder.
The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The preset disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to express reduced levels of NR4A3 gene and/or NR4A3 protein. Also provided are modified cells, e.g., immune cell, which have been modified to express reduced levels of NR4A3 gene and/or NR4A3 protein. Reducing levels of NR4A3 gene and/or NR4A3 protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
The present disclosure provides methods of culturing reprogrammed cells in a medium comprising a phosphoAKT inhibitor, metformin, an mTOR inhibitor, 2DG, or any combination thereof. In some aspects, the medium further comprises at least about 5 mM potassium ion. In some aspects, the methods disclosed herein increases the number of stem-like redirected T cells in the population of cells, while maintaining or improving target-cell killing activity. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
The present disclosure provides targeted IL-12 affinity variants, pharmaceutical compositions comprising the variants, therapeutic cells expressing the variants, and methods or uses of the same for the treatment or prevention of a disease or disorder.
e.g.e.g.e.g., to comprise a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). In some aspects, the cells are administered to a subject in need thereof.
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the sternness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to exhibit a reduced expression of a member of the NR4A family (e.g., NR4A1, NR4A2, and/or NR4A3) and an increased expression of a c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to exhibit a reduced expression of a member of the NR4A family (e.g., NR4A1, NR4A2, and/or NR4A3). In some aspects, the immune cells are administered to a subject in need thereof.
The present disclosure provides compositions and methods for improving immune cell therapy. In particular aspects, the present disclosure relates to expression construct(s) expressing a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric stimulating receptor (CSR) that both specifically target glypican 3 (GPC3), along with a human c-Jun polypeptide.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The preset disclosure provides chimeric activation receptors comprising (i) a TGFβ-binding domain and (ii) a CD2 costimulatory domain. In some aspects, the TGFβ-binding domain comprises an extracellular domain of a TGFβ receptor. Other aspects of the disclosure are directed to nucleic acid molecules encoding a chimeric activation receptor, cells comprising the chimeric activation receptor and/or a nucleic acid molecule encoding the same, and methods of use thereof in the treatment of a disease or condition (e.g., a tumor) in a subject in need thereof.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and/or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a region within the NR4A3 gene. The present disclosure also provides the use of such polynucleotides to treat various diseases or disorders.
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to express a ROR1-binding protein and have increased level of c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.
The present disclosure provides IL-12 affinity variants, pharmaceutical compositions comprising the variants, therapeutic cells expressing the variants, and methods or uses of the same for the treatment or prevention of a disease or disorder.
The present disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion. In some aspects, the methods disclosed herein increase the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). In some aspects, the cells are administered to a subject in need thereof.
The preset disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion. In some aspects, the methods disclosed herein increase the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). In some aspects, the cells are administered to a subject in need thereof.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
26.
METHODS FOR CULTURING CELLS EXPRESSING ROR1-BINDING PROTEIN
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to express a ROR1-binding protein and have increased level of c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof.
The present disclosure provides engineered human cells (e.g., T cells) for treatment. Also provided are expression constructs for making the engineered cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
30.
NR4A-DEFICIENT CELLS EXPRESSING C-JUN AND USES THEREOF
The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
NR4A3e.gNR4A3NR4A3NR4A3 gene and/or NR4A3 protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.
Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codon-optimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.
Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codonoptimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.
The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
e.g(e.g. e.g. e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (Royaume‑Uni)
Inventeur(s)
Jensen, Helle Groothaert
Sather, Blythe D.
Lynn, Rachel C.
Boldajipour, Bijan A.
Hiraragi, Hajime
Potluri, Shobha
Fukuda, Rachel A.
Murt, Megan L.
Park, Spencer
Vong, Queenie M.
Wang, Ying
Christ, Nicole
Mendes, Oliver Jon
Abrégé
The present application concerns engineered human cells T cells expressing a NY-ESO-1 tumor antigen-targeted TCR, which are enhanced by co-expression with c-jun in the vectors used to transform the cells; these cells are for use in cancer therapy. Also provided are expression constructs for making such engineered cells, in particular an expression construct comprising one or more expression cassettes for expressing: (a) a T cell receptor (TCR) that specifically binds to a peptide from a human NY-ESO-1 protein complexed with an HLA-A molecule; and (b) a human c-Jun polypeptide. The c-Jun polypeptide can be the human wild type c-Jun or a mutant human c-Jun.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/00 - Préparations médicinales contenant des peptides
The present disclosure provides engineered human cells (e.g., T cells) for treatment. Also provided are expression constructs for making the engineered cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+ TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof.
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+ TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof.
17667030.1
The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer
(2) Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer. Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer. Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer.
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+TILs, relative to CD4+e.g. e.g.e.g.e.g., the TILs, are administered to a subject in need thereof.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer
(2) Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
47.
Methods for making, compositions comprising, and methods of using rejuvenated T cells
The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.
The preset disclosure provides chimeric activation receptors comprising (i) a TGFβ-binding domain and (ii) a CD2 costimulatory domain. In some aspects, the TGFβ-binding domain comprises an extracellular domain of a TGFβ receptor. Other aspects of the disclosure are directed to nucleic acid molecules encoding a chimeric activation receptor, cells comprising the chimeric activation receptor and/or a nucleic acid molecule encoding the same, and methods of use thereof in the treatment of a disease or condition (e.g., a tumor) in a subject in need thereof.
C12N 5/078 - Cellules du sang ou du système immunitaire
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
49.
STIM-R (SYNTHETIC T CELL IMMUNE MICROENVIRONMENT-REPROGRAMMING)
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical, biological and biochemical products for research and scientific purposes; reagents for programmable culturing of biological material; reagents for use in biotechnology. Pharmaceutical, medical and veterinary preparations; reagents for the processing and culturing of biological material for medical purposes; chemical, biological and biochemical preparations for medical purposes; chemical, biological and biochemical products for medical purposes; reagents for use in biological treatment. Medical, pharmaceutical and biotechnological research; Scientific and technological services, and biological research and development relating thereto. Medical services.
50.
STIM-R (SYNTHETIC T CELL IMMUNE MICROENVIRONMENT-REPROGRAMMING)
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Chemical, biological and biochemical products for research, scientific and medical purposes; reagents for programmable culturing of biological material; reagents for use in biotechnology and in biological treatment
(2) Pharmaceutical, medical and veterinary preparations; reagents for the processing and culturing of biological material; chemical, biological and biochemical preparations (1) Scientific and technological services, and biological research and development relating thereto
(2) Medical, pharmaceutical and biotechnological research; medical services
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells, in the field of cancer treatment, auto-immune diseases, and infectious diseases; scientific and technological services and biological research and development, namely, research and development in the field of the treatment of cancer Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells, in the field of cancer treatment, auto-immune diseases, and infectious diseases; scientific and technological services and biological research and development, namely, research and development in the field of the treatment of cancer Medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.
The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases, namely, respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; cells for medical or clinical purposes, namely, genetically modified immune cells made from human blood cells for cell therapy, epigenetically modified immune cells made from human blood cells for cell therapy, rejuvenated and partially reprogrammed human blood cells for cell therapy, biological preparations made from human immune blood cells, rejuvenated somatic cells, and rejuvenated and partially reprogrammed human blood cells for the treatment of cancer; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of stem cells for medical purposes and pharmaceutical preparations for the treatment of cancer, auto-immune diseases, and infectious diseases, namely, respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases (1) custom manufacturing services of pharmaceuticals
(2) Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development in the field of pharmaceuticals; scientific medical research laboratory services; medical and scientific research in the field of pharmaceuticals and cell therapy; scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer
(3) Medical services in the nature of information, advisory and consultancy services in the field of medical testing services; medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations for medical or clinical purposes. Manufacturing services, namely, custom manufacture of pharmaceuticals and drugs. Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development; scientific laboratory services; medical and scientific research; scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer. Medical services; medical services, namely, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; medical services for treatment of cancer.
The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and drugs for the treatment of cancer;
cells for medical or clinical purposes; pharmaceutical preparations for
cell therapy for medical or clinical purposes; pharmaceutical
preparations for gene therapy for medical or clinical purposes; kits
comprised of cells and pharmaceutical preparations for medical or
clinical purposes Pharmaceutical research and development; development of
pharmaceutical preparations and drugs; development of
pharmaceutical preparations and drugs for the treatment of cancer;
development of pharmaceutical preparations and drugs in the field of
immunotherapy; development of pharmaceutical preparations and
drugs in the field of cell therapy; scientific research and development;
medical and scientific research; biological research and
development, namely, research and development utilizing integrated
technology platforms combining chemical, molecular, genetic, protein
and cell systems engineering technologies for therapeutic regulation
of cells and cell systems, namely, therapeutic regulation of immune
cells; biological research and development, namely, research and
development related to treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and drugs for the treatment of cancer;
cells for medical or clinical purposes; pharmaceutical preparations for
cell therapy for medical or clinical purposes; pharmaceutical
preparations for gene therapy for medical or clinical purposes; kits
comprised of cells and pharmaceutical preparations for medical or
clinical purposes Pharmaceutical research and development; development of
pharmaceutical preparations and drugs; development of
pharmaceutical preparations and drugs for the treatment of cancer;
development of pharmaceutical preparations and drugs in the field of
immunotherapy; development of pharmaceutical preparations and
drugs in the field of cell therapy; scientific research and development;
medical and scientific research; biological research and
development, namely, research and development utilizing integrated
technology platforms combining chemical, molecular, genetic, protein
and cell systems engineering technologies for therapeutic regulation
of cells and cell systems, namely, therapeutic regulation of immune
cells; biological research and development, namely, research and
development related to treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases, namely, sexually transmitted diseases, respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, and eczema; cells for medical or clinical purposes, namely, genetically modified human immune cells for cell therapy, epigenetically modified human immune cells for cell therapy, rejuvenated and partially reprogrammed human cells for cell therapy, biological preparations made from human immune cells, rejuvenated somatic cells, and rejuvenated and partially reprogrammed human cells for the treatment of cancer; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of genetically modified human immune cells for cell therapy, epigenetically modified human immune cells for cell therapy, rejuvenated and partially reprogrammed human cells for cell therapy, biological preparations made from human immune cells, rejuvenated somatic cells, and rejuvenated and partially reprogrammed human cells for the treatment of cancer cells for medical purposes and pharmaceutical preparations for the treatment of sexually transmitted diseases, cancer, auto immune diseases, and infectious diseases, namely, sexually transmitted diseases, respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, and eczema (1) Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development in the field of pharmaceuticals and biopharmaceuticals; medical research laboratory services; medical and scientific research in the field of pharmaceuticals and biopharmaceuticals; conducting clinical trial regarding pharmaceutical preparations and drugs for the treatment of cancer, auto immune diseases, and infectious diseases; conducting clinical trial regarding pharmaceutical preparations and drugs in the field of immunotherapy; conducting clinical trial regarding pharmaceutical preparations and drugs in the field cell therapy
(2) Medical services in the nature of information, advisory and consultancy services in the field of medical testing services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals preparations and drugs; pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; Cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations for medical or clinical purposes. Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development; scientific laboratory services; conducting clinical trial regarding pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; conducting clinical trial regarding pharmaceutical preparations and drugs in the field of immunotherapy; conducting clinical trial regarding pharmaceutical preparations and drugs in the field cell therapy; medical and scientific research. medical care services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations and drugs for the treatment of cancer; cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations for medical or clinical purposes Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development; medical and scientific research
